Skip to main content

Table 6 Treatment selection: Proportion of therapies for post-menopausal ER+, HER2- metastatic BC patients used in first-line, second-line and third-line in the past 6 months – from physician survey (n = 103)

From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

  First Line Second Line Third Line
Treatment Mean SD Mean SD Mean SD
Oral hormonal therapy (e.g., tamoxifen, aromatase inhibitors) 51.91% 32.48 21.14% 22.40 12.55% 15.02
Other hormonal (e.g., fulvestrant) 11.68% 17.54 21.66% 23.76 16.32% 19.98
Chemotherapy 17.55% 18.43 25.58% 23.12 35.83% 27.27
Exemestane plus Everolimus 9.50% 14.44 22.38% 24.41 21.26% 23.71
Avastin plus chemotherapy 4.19% 9.73 4.91% 10.44 6.17% 14.42
Clinical trial 1.90% 6.16 2.34% 6.20 3.89% 9.27
Other 3.25% - 2.00% - 3.97% -
  1. BC Breast cancer; SD standard deviation